Welcome to our dedicated page for Dexcom news (Ticker: DXCM), a resource for investors and traders seeking the latest updates and insights on Dexcom stock.
Dexcom Inc (DXCM) is a leader in continuous glucose monitoring systems, transforming diabetes care through real-time health data solutions. This page consolidates official announcements, financial updates, and strategic developments for stakeholders tracking the company’s progress in medical technology.
Access timely updates on product innovations, regulatory milestones, and partnership agreements that shape Dexcom’s position in the diabetes management sector. Investors will find earnings reports and market analyses, while healthcare professionals can monitor clinical trial outcomes and device enhancements.
Key content includes FDA clearances, international expansion updates, and technology integration developments with insulin delivery systems. All materials are sourced from verified channels to ensure reliability for research and decision-making.
Bookmark this page for streamlined access to Dexcom’s latest advancements in CGM technology and related financial performance. Check regularly for critical updates that impact both patient care and investment considerations.
Dexcom's G6 Continuous Glucose Monitoring (CGM) System is being used by astronauts on the Polaris Dawn mission to study the effects of spaceflight on human health, particularly glucose regulation. This marks a significant milestone for Dexcom (NASDAQ: DXCM) as the first use of their CGM technology in space. The mission will conduct about 40 scientific experiments over five days, exploring how microgravity and space conditions impact glucose health.
Dexcom is collaborating with Labfront to provide advanced analytics for the collected data. This research is important for understanding metabolic responses in space and ensuring space travel is inclusive for people with diabetes. The company recently launched Stelo, the first FDA-cleared glucose biosensor for non-prescription use by adults not using insulin, further expanding their portfolio of glucose monitoring solutions.
Dexcom (NASDAQ: DXCM) is set to showcase its Continuous Glucose Monitoring (CGM) technology at the EASD 2024 Conference Symposium. The event will feature expert panelists discussing the transformational effects of Dexcom CGM on clinical practice. Key highlights include:
1. Dexcom's position as the most experienced partner in Automatic Insulin Delivery (AID), powering more AID systems than any other CGM brand.
2. Studies showing Dexcom CGM's potential to support therapy de-escalation and optimize management in Type 2 diabetes.
3. Recent data indicating that 100% of Dexcom CGM users with Type 2 diabetes made dietary changes, and 91% felt empowered to manage their condition.
4. Evidence of long-term cost savings for healthcare systems across Europe.
Dexcom (NASDAQ: DXCM) has announced that its top executives will present at the 2024 Wells Fargo Healthcare Conference on September 4th. Kevin Sayer, Chairman, President and CEO, along with Jereme Sylvain, Executive VP and CFO, will provide an update on the company. The presentation is scheduled for 11:00 AM EST and will be webcast live.
Investors and interested parties can access the webcast through the Dexcom Investor Relations website at investors.dexcom.com. The presentation will also be archived on the site for future reference, allowing those unable to attend the live event to catch up later.
Dexcom has launched Stelo, the first over-the-counter glucose biosensor in the U.S., now available for purchase without a prescription at Stelo.com. Designed for people with Type 2 diabetes not using insulin and those with prediabetes, Stelo provides 24/7 glucose insights directly to a smartphone, revealing how food, exercise, and sleep affect glucose levels.
Key features of Stelo include:
- No fingersticks required
- Up to 15-day wear time
- Waterproof design
- Personalized app with spike and pattern detection
- Proven results in lowering A1c and potentially slowing diabetes progression
Dexcom, Inc. (NASDAQ: DXCM) announced that its Dexcom G7 Continuous Glucose Monitoring (CGM) System will be added to the Régie de l'assurance maladie du Québec (RAMQ) Public Prescription Drug Insurance Plan. This expansion brings coverage to Québec residents ages two and older living with type 1 diabetes who meet eligibility criteria. Launched in Canada in 2023, Dexcom G7 is described as the most accurate CGM system available, clinically proven to lower A1C and increase time in range. The system allows users to easily monitor glucose levels and make informed decisions about insulin, food, and activity without routine fingersticks or scanning. This coverage expansion follows similar announcements in other Canadian provinces, making advanced diabetes management technology more accessible and reducing out-of-pocket costs for eligible individuals.
Tandem Diabetes Care and Dexcom have announced that the t:slim X2 insulin pump with Dexcom G7 CGM compatibility has been authorized for sale by Health Canada. This integration makes it the only Automated Insulin Delivery (AID) system in Canada compatible with both Dexcom G7 and G6 CGM technologies. The updated software is expected to be commercially available this fall, with existing users receiving a free remote update.
Key features of the integration include:
- Dexcom G7's smaller, all-in-one sensor and transmitter
- 30-minute sensor warmup time
- 12-hour grace period for sensor replacement
- Increased connectivity with digital health apps
The t:slim X2 pump with Control-IQ technology is rated as the #1 AID system in Canada, offering customizable profiles and various infusion set options.
Dexcom reported its Q2 2024 financial results, with revenue growing 15% year-over-year to $1.004 billion. U.S. revenue grew 19% while international revenue increased 7%. GAAP operating income was $158.0 million, or 15.7% of revenue. The company updated its 2024 guidance, projecting revenue of $4.00-4.05 billion (11-13% organic growth). Dexcom also announced a $750 million share repurchase program.
Strategic highlights include launching Direct-to-Watch in the U.S. and international markets, securing coverage for Dexcom ONE in France for type 2 diabetes patients on basal insulin, and advancing pump connectivity with Insulet and Tandem Diabetes Care. However, CEO Kevin Sayer noted that execution did not meet their high standards, and the company is taking action to improve.
Dexcom (NASDAQ: DXCM) has announced that it will release its second quarter 2024 financial results on Thursday, July 25, 2024, after market close. The company will also host a conference call at 4:30 p.m. Eastern Time on the same day to discuss its performance.
The call will be webcast live and available on the Dexcom investor relations website. Participants can join the call by dialing (877) 344-3040 for US/Canada or (646) 475-1647 for international callers, using the confirmation ID '9430114'.
The webcast will be archived on the website for future reference.
Dexcom, a leader in real-time continuous glucose monitoring (CGM), announced the integration of its Dexcom G6 CGM with the Omnipod® 5 Automated Insulin Delivery (AID) System in the Netherlands. This deployment aims to improve diabetes management for the 100,000 individuals with Type 1 diabetes in the country, including 10,000 children. The system is the first tubeless Hybrid Closed Loop (HCL) approved for children in the Netherlands and promises significant health benefits, including increased time in range (+11.5%) and reduced HbA1c levels. The Dexcom G6 is highly water-resistant and allows remote monitoring via the 'Follow' app, giving users and caregivers more flexibility and peace of mind. The Dexcom G6 is reimbursed by Dutch health insurers for children (18 and under), pregnant women, women trying for pregnancy, and Type 1 hypo unaware users.
Dexcom presented significant clinical data at the ADA 2024 conference, emphasizing the benefits of Dexcom CGM for people with Type 2 diabetes. The data highlights meaningful decreases in A1C and improved time in range for users of Dexcom CGM. Dexcom introduced new integrations with the Omnipod 5 Automated Insulin Delivery System and showcased updates to the Dexcom G7 app, including direct connectivity to Apple Watch. Dexcom G7's enhanced Bluetooth range and rapid reconnect features further enhance user experience. The studies also indicate that CGM is beneficial even for Type 2 diabetes patients not on insulin and those with prediabetes, demonstrating improved health behaviors and psychosocial health.
FAQ
What is the current stock price of Dexcom (DXCM)?
What is the market cap of Dexcom (DXCM)?
